HYTN Innovations

HYTN Innovations Inc. is a Canadian pharmaceutical company specializing in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids and psilocybe-derived tryptamines. Operating out of its GMP-certified facility in Kelowna, British Columbia, the company holds a Health Canada Drug Establishment Licence (DEL) and a Cannabis Drug Licence (CDL), enabling it to manufacture active pharmaceutical ingredients (APIs) and finished dosage forms. HYTN serves both domestic and international medical cannabis markets, including Germany, the United Kingdom, and Australia. Additionally, the company has developed a peptide drug development business focused on a pre-clinical subcutaneous injectable BPC-157 drug candidate for refractory ligament disorders, which it plans to spin out into a dedicated public entity.